IMNM (Immunome) Short Percentage of Float


IMNM Immunome Inc IMNM
44 GF Score
Price $19.97
GF Value $2.02
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Immunome Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

IMNM vs CLDX, ELVN, VERA: Short Percentage of Float Comparison

For the Biotechnology subindustry, Immunome's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunome Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunome's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Immunome's Short Percentage of Float falls into.


IMNM
44GF Score
Immunome Inc IMNM
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Immunome (IMNM) Overvalued in 2026?

Based on GuruFocus' analysis, Immunome stock appears to be overvalued. The current stock price of $19.97 is trading 888.6% above its estimated GF Value™ of $2.02. GuruFocus considers Immunome to be Significantly Overvalued.

Key valuation signals for IMNM:

  • Short Percentage of Float:
  • GF Value™: $2.02 vs. price of $19.97 (888.6% above fair value)
  • GF Score™: 44/100 with 1 warning sign

No single metric tells the full story. See the IMNM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immunome Business Description

Address 18702 N. Creek Parkway, Suite 100, Bothell, WA, USA, 98011
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
44GF Score

Get the complete analysis for IMNM

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.97
Price
$2.02
GF Value